Latest news
Positive Phase 2b ICONA interim results for icosabutate in NASH patients
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeksOnce-daily oral icosabutate showed dose-dependent,...
BioGeneration Ventures BGV IV fund closes at €140 million
BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension,...
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, The Netherlands, 6 January 2021 – Intravacc, one of the leading translational research and...
Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies
The four-year agreement provides benefits for portfolio companies of Forbion and BioGeneration Ventures (BGV) Lonza to provide de-risking, development and manufacturing services for large molecule biologics The agreement will streamline the gene to IND process,...
Next events
11-15 January 2021: Biotech Showcase and 2021 BIO One-on-One Partnering @ JPM
The BGV team will be attending at the Biotech Showcase and 2021 BIO One-on-One Partnering @ JPM Find more information here and here.